Aurora Cannabis Announces Fiscal 2021 Second Quarter Results
News provided by
Share this article
Share this article
Total Cannabis Net Revenue of $70.3 Million, Excluding Provisions of $2.7 Million, Up 11% over Q2 2020
Medical Cannabis Net Revenue of $38.9 Million, Up 42% Versus Q2 2020, Driven by a 562% Increase in High Margin International Medical Sales
Adjusted EBITDA Loss, excluding Provisions and Termination Costs, of $12.1 Million Represents an Improvement of $53.1 Million Over Q2 2020; Current Loss Triggered by Several Decisions Expected to Boost Long-Term Profitability
Improved Cash Use by More Than 74% Versus Q2 2020; Cash on Hand at February 10, 2021 of $565 Million
NYSE | TSX: ACB
Company or
Aurora ) (NYSE: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, today announced its financial and operational results for the second quarter of fiscal 2021 ended December 31, 2020.